Back to search
HER2-positive Gastric Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which HER2-positive Gastric Cancer trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which HER2-positive Gastric Cancer trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2…
This phase II trial studies if talazoparib works in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or dist…
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination w…
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER…
The safety, tolerability, and determination of the maximum tolerated dose (MTD) of the combination therapy were first evaluated for IAH0968 in combination with…
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junc…
Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.…
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.